Xilio Therapeutics, Inc. (XLO) Q1 2026 Earnings
Xilio Therapeutics, Inc. reported Q1 2026 revenue of $12.7M (+331.7% YoY), beat analyst consensus of $8.5M by $4.1M. Diluted EPS came in at $-0.58 (-222.2% YoY), beat the $-0.66 consensus by $0.08.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Xilio Therapeutics, Inc.'s Q1 2026 earnings report.
Xilio Therapeutics, Inc. (XLO) reported Q1 2026 earnings on May 12, 2026 before market open.
Xilio Therapeutics, Inc. reported revenue of $12.7M and diluted EPS of $-0.58 for Q1 2026.
Revenue beat the consensus estimate of $8.5M by $4.1M. EPS beat the consensus estimate of $-0.66 by $0.08.
Compared to the same quarter a year prior, revenue grew 331.7% from $2.9M a year earlier and diluted EPS declined 222.2% from $-0.18.
You can read the 8-K earnings release (0001193125-26-218194) and the 10-Q periodic report (0001193125-26-218200) directly on SEC EDGAR. The filing index links above go to sec.gov.